Level C· Early human research exploring benefitsCase Report / SeriesEurope PMC

Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study

Murugesan N., Woodard K., Ramaraju R., Greenway FL., Coulter AA., Rebello CJ.

Case Report / Series on Type 2 Diabetes, published in J Med Food (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
J Med Food (2020)
Reported sample size
—
Source database
Europe PMC
PMID
31670603
PMCID
PMC7087405
DOI
10.1089/jmf.2019.0216
Citations
24

Abstract (original English)

Our studies in primary human adipocytes show that naringenin, a citrus flavonoid, increases oxygen consumption rate and gene expression of uncoupling protein 1 (UCP1), glucose transporter type 4, and carnitine palmitoyltransferase 1 β (CPT1 β ). We investigated the safety of naringenin, its effects on metabolic rate, and blood glucose and insulin responses in a single female subject with diabetes. The subject ingested 150 mg naringenin from an extract of whole oranges standardized to 28% naringenin three times/day for 8 weeks, and maintained her usual food intake. Body weight, resting metabolic rate, respiratory quotient, and blood chemistry panel including glucose, insulin, and safety markers were measured at baseline and after 8 weeks. Adverse events were evaluated every 2 weeks. We also examined the involvement of peroxisome proliferator-activated receptor α (PPAR α ), peroxisome proliferator-activated receptor γ (PPAR γ ), protein kinase A (PKA), and protein kinase G (PKG) in the response of human adipocytes to naringenin treatment. Compared to baseline, the body weight decreased by 2.3 kg. The metabolic rate peaked at 3.5% above baseline at 1 h, but there was no change in the respiratory quotient. Compared to baseline, insulin decreased by 18%, but the change in glucose was not clinically significant. Other blood safety markers were within their reference ranges, and there

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansCitrus sinensisInsulin ResistanceFlavanonesInsulinCarnitine O-PalmitoyltransferaseBlood GlucosePPAR alphaPPAR gammaPlant Extracts

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research